Analyst Price Targets — LUCD
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| March 25, 2025 11:25 am | — | BTIG | $2.00 | $1.55 | TheFly | Lucid Diagnostics price target lowered to $2 from $2.50 at BTIG |
| November 13, 2024 5:31 pm | Mike Matson | Needham | $2.50 | $0.79 | StreetInsider | Needham Reiterates Buy Rating on Lucid Diagnostics Inc (LUCD) |
| May 14, 2024 8:01 am | Kyle Mikson | Canaccord Genuity | $3.00 | $0.95 | StreetInsider | Canaccord Genuity Reiterates Buy Rating on Lucid Diagnostics Inc (LUCD) |
| April 8, 2024 7:51 am | Mark Massaro | BTIG | $2.50 | $0.93 | StreetInsider | BTIG updates Lucid Diagnostics Inc (LUCD) model post Q4 results |
| November 18, 2022 7:52 am | — | BTIG | $3.50 | $1.91 | Benzinga | BTIG Maintains Buy on Lucid Diagnostics, Lowers Price Target to $3.5 |
| November 15, 2022 5:49 am | — | Needham | $3.10 | $2.27 | Benzinga | Needham Maintains Buy on Lucid Diagnostics, Lowers Price Target to $3.1 |
Latest News for LUCD
NEW YORK, April 9, 2026 /PRNewswire/ -- Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Company"), a commercial-stage, cancer prevention medical diagnostics company and subsidiary of PAVmed Inc. (Nasdaq: PAVM), today announced that Lishan Aklog, M.D., Lucid's Chairman and Chief Executive Officer, will participate in a fireside chat at the 25th Annual Needham Virtual Healthcare Conference on Thursday, April…
Medtech industry veteran to oversee development and commercialization of PAVmed's current and future medical device portfolio. Octeris, Inc. subsidiary formed to advance endoscopic esophageal imaging technology recently licensed from Duke University.
PAVmed strengthened its capital structure and relaunched its medical device portfolio under new leadership Veris Health advanced strategic partnership with OSU and progressed implantable physiological monitor toward FDA submission Lucid Diagnostics expanded EsoGuard healthcare system access and clinical evidence base Conference call and webcast to be held today, March 30, at 8:30 AM EST NEW YORK, March 30, 2026…
Lucid Diagnostics (NASDAQ: LUCD) reported higher fourth-quarter 2025 EsoGuard testing volume and revenue and highlighted progress on reimbursement initiatives, including a new U.S. Department of Veterans Affairs (VA) contract and ongoing discussions with Medicare and commercial payers. Fourth-quarter test volume exceeded company's target range Chairman and CEO Dr. Lishan Aklog said fourth-quarter EsoGuard test…
Shares of Lucid Diagnostics Inc. (NASDAQ: LUCD - Get Free Report) have been assigned an average recommendation of "Moderate Buy" from the five ratings firms that are currently covering the company, Marketbeat Ratings reports. One analyst has rated the stock with a sell rating and four have given a buy rating to the company. The average
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for LUCD.
U.S. House Trading
No House trades found for LUCD.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.